A renewed web presence for cerbomed GmbH
|Pressemitteilung von: cerbomed GmbH|
www.cerbomed.com patients and
their families, as well as doctors, and medical specialists can access tailored
information on transcutaneous Vagus Nerve Stimulation (t-VNS), using the device
NEMOS. The new therapy alternative for difficult-to-treat epilepsies and
depression will be available in Germany in summer 2012.
- ERLANGEN, Germany, March 8th, 2012 – The German medical device company
cerbomed GmbH is re-launching its web site. At |
The new web-presence marks cerbomed as a provider of innovative therapies.
Transcutaneous Vagus Nerve Stimulation is addressed to patients suffering from various difficult to treat neurological and psychiatric diseases. The t-VNS therapy uses the fact that a branch of the vagus nerve is located directly under the skin in areas of the outer ear and therefore can be stimulated through the skin (transcutaneously) with electrical impulses.
For t-VNS cerbomed developed and patented a special stimulator and a dedicated ear electrode. The stimulator, which is connected with the ear electrode, sends out the electrical impulses. With the transcutaneous vagus nerve stimulator NEMOS a targeted stimulation of the vagus nerve gets possible without the need of a surgery.
The German market entry for NEMOS is planned for the third quarter of 2012. NEMOS will then be available for patients suffering from hard-to-treat epilepsies and depression.
Cerbomed GmbH is an innovative medical device company that concentrates on researching, developing and producing new technologies and products for neuromodulation. The company’s focus is on transcutaneous Vagus Nerve Stimulation (t-VNS), which may offer an attractive therapy option for patients with hard-to-treat neurological and psychiatric illnesses.
In 2011 cerbomed received the European clearance (CE mark) for the transcutaneous vagus nerve stimulator NEMOS. In early 2012 two more clinical studies will be starting regarding the effectiveness of t-VNS in patients with drug-resistant epilepsy and chronic migraine.
Dr. Martin Hyca, Director Marketing
+49 9131 9202 76 30